Principal Investigator
Jose Lutzky
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20221372
Clinical Trial Summary
A Phase 1/2, open-label study of PD-1 knockout tumor-infiltrating lymphocytes (IOV-4001) in participants with unresectable or metastatic melanoma or Stage III or IV non-small-cell lung
cancer
Phase
Phase I/II
Funding Agency/Sponsor
Industrial
Disease
Cutaneous Malignancies
Contact Information
Phone Number
305-243-2647